US 12,310,973 B2
Administration and dosage of diaminophenothiazines
Claude Michel Wischik, Aberdeen (GB); Björn Olaf Schelter, Aberdeen (GB); Damon Jude Wischik, Cambridge (GB); and John Mervyn David Storey, Aberdeen (GB)
Assigned to WisTa Laboratories Ltd., Singapore (SG)
Filed by WisTa Laboratories Ltd., Singapore (SG)
Filed on Apr. 6, 2023, as Appl. No. 18/131,570.
Application 18/131,570 is a continuation of application No. 17/961,765, filed on Oct. 7, 2022, granted, now 12,128,051.
Application 17/961,765 is a continuation of application No. 17/349,427, filed on Jun. 16, 2021, granted, now 11,759,469.
Application 17/349,427 is a continuation of application No. 16/320,148, granted, now 11,065,256, previously published as PCT/EP2017/068749, filed on Jul. 25, 2017.
Claims priority of application No. 1612863 (GB), filed on Jul. 25, 2016; and application No. 1710382 (GB), filed on Jun. 29, 2017.
Prior Publication US 2023/0346794 A1, Nov. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5415 (2006.01); A23L 33/105 (2016.01); A23L 33/12 (2016.01); A23L 33/15 (2016.01); A23P 10/28 (2016.01); A23P 10/30 (2016.01); A61K 45/06 (2006.01); A61P 25/28 (2006.01); B65D 75/36 (2006.01)
CPC A61K 31/5415 (2013.01) [A23L 33/105 (2016.08); A23L 33/12 (2016.08); A23L 33/15 (2016.08); A23P 10/28 (2016.08); A23P 10/30 (2016.08); A61K 45/06 (2013.01); A61P 25/28 (2018.01); B65D 75/36 (2013.01); A23V 2002/00 (2013.01); B65D 2203/02 (2013.01)] 32 Claims
 
1. A method of therapeutic treatment of a disorder of protein aggregation which is mild cognitive impairment or Alzheimer's disease in a subject,
which method comprises orally administering to said subject a methylthioninium (MT)-containing compound,
wherein said administration provides a total daily dose of between 0.5 and 20 mg of MT to the subject per day, wherein the MT-containing compound is characterized by a purity of greater than 97% and wherein the MT-containing compound is methylthioninium chloride (MTC), or a hydrate thereof.